Clinical trials
Prostate cancer clinical trials
Cancer of the prostate gland, one of the most common cancers in men. We’re tracking 1,212 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05915442RecruitingPhase 2
Adenosine blocker plus immunotherapy for limited prostate spread
This Phase 2 study tests a medicine that affects “adenosine” signaling along with an immune checkpoint inhibitor (immunotherapy) in men with hormone-sensitive prostate cancer that has spread in only a small, limited way. It aims to stop or slow that limited spread by helping the immune system work better.
New York, New YorkAges 18–99 - NCT07072728RecruitingPhase 2
Psilocybin therapy for anxiety in cancer patients
This trial tests whether psilocybin (a psychedelic drug given with talk therapy) can help people with cancer who have adjustment disorder—a condition where a cancer diagnosis causes severe anxiety or stress. It focuses on reducing anxiety and improving emotional well-being.
Abbotsford, VictoriaAges 18–80 - NCT06960291Recruiting
EXCEL Exercise Program for Cancer Patients in Canada
This study tests a national exercise program called EXCEL for people with cancer. It helps you start or continue safe physical activity to manage side effects and improve your well-being.
Calgary, AlbertaAges 18 years+ - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05191680RecruitingPhase 2
Testing apalutamide in early prostate cancer active surveillance
This Phase 2 trial tests whether apalutamide can help people with early prostate cancer who choose active surveillance. It uses MRI and biopsy results to confirm the cancer type and location, then checks if treatment is safe and potentially helpful.
Cambridge, CambridgeshireAges 18 years+ - NCT06864572Enrolling by invitationEarly Phase 1
New imaging tracer for metastatic prostate cancer
This trial tests a new radioactive tracer that may help doctors see and treat prostate cancer that has spread. The tracer attaches to cancer cells so they show up on scans, and may also help guide treatment.
BeijingAges 18–85 - NCT05582772Recruiting
Supportive care for older men with metastatic prostate cancer
This study tests a phone-based supportive care program for older men with prostate cancer. It aims to help with day-to-day management while you’re receiving hormone-related cancer treatment.
Toronto, OntarioAges 65 years+ - NCT06776172Recruiting
Lymph node removal during prostate surgery: a comparison study
This trial tests whether removing pelvic lymph nodes during prostate cancer surgery improves outcomes for men with high-risk prostate cancer. If you have high-risk prostate cancer and no signs of spread, you may be able to join.
AarauAges 18 years+ - NCT06851663RecruitingPhase 2/Phase 3
New PET scan for many solid tumors
This trial tests a new type of PET scan that uses a special antibody to find a marker called Trop2 on many common solid tumors. It may help doctors see tumors more clearly without needing a biopsy.
ShanghaiAges 18–75 - NCT06800313RecruitingPhase 1/Phase 2
A study of HLD-0915 for metastatic prostate cancer
This trial tests a new drug called HLD-0915 in men with prostate cancer that has spread. It aims to see how well the drug works and if it's safe.
Colorado Springs, ColoradoAges 18 years+ - NCT06723665Enrolling by invitation
PET/CT scan for prostate cancer patients
This study uses a special type of PET/CT scan called 18F-PSMA-1007 to take detailed pictures of prostate cancer. It's for people who might have prostate cancer, have been diagnosed, or need to check how their cancer is doing after treatment.
Wuxi, JiangsuAges 40–75 - NCT06651359Recruiting
Mobile health app for Black prostate cancer survivors
This study tests a mobile health app (mHealth) designed to help Black prostate cancer survivors improve their quality of life. It aims to see if using the app can make daily life better after treatment.
Tallahassee, FloridaAges 18 years+ - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06582628RecruitingPhase 2
Talazoparib and enzalutamide for advanced prostate cancer after prior treatment
This trial tests a combination of two drugs, talazoparib and enzalutamide, in men with advanced prostate cancer that has progressed after previous treatment with a hormone therapy called an AR inhibitor. It aims to see if this combination can help control the cancer and delay further progression.
BordeauxAges 18 years+ - NCT06508567Recruiting
MRI-Guided Internal Radiation for Returning Prostate Cancer
This trial tests a new way to use a type of internal radiation (high-dose-rate brachytherapy) guided by MRI to treat prostate cancer that has come back in the same area after previous radiation therapy. It is designed to be more precise and hopefully safer while using the latest PSMA PET scans to make sure the cancer hasn't spread.
Toronto, OntarioAges 18 years+ - NCT06470685Enrolling by invitation
Preventive prostate removal for prostate cancer risk
This study tests whether removing the prostate before cancer develops can help people at higher risk, such as those with certain gene changes (like BRCA2), a strong family history, or Black African/Caribbean ancestry. It also includes people who have already had their prostate removed for cancer treatment.
LondonAges 18 years+ - NCT05324332Recruiting
Two scans to study prostate cancer in the same group
This trial looks at prostate cancer patients who have not started treatment yet and have two different PET/CT scans close together. It may help doctors compare how these scans show prostate cancer in the body.
Beijing, Beijing MunicipalityAges 18–90 - NCT06335914Recruiting
Dual PET scans for advanced prostate cancer
This study tests whether two kinds of PET scans, one targeting PSMA and one targeting sugar uptake (FDG), can help doctors better understand advanced prostate cancer. If you have prostate cancer that has spread (metastatic) and still responds to hormone therapy, the scans may help guide your treatment.
Toronto, OntarioAges 18 years+ - NCT06267729RecruitingPhase 1/Phase 2
A new cell therapy for advanced prostate cancer
This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.
Duarte, CaliforniaAges 18–130 - NCT06236139RecruitingPhase 1/Phase 2
Immune cells plus hormone therapy for advanced prostate cancer
This study tests a new type of treatment that uses your own immune cells (engineered to target prostate cancer) combined with a hormone therapy drug. It is for men with advanced prostate cancer that has stopped responding to standard hormone treatments.
Seattle, WashingtonAges 18 years+ - NCT06217822RecruitingPhase 1
Testing a new radiation therapy for advanced prostate cancer
This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.
Duarte, CaliforniaAges 18 years+ - NCT06085729RecruitingPhase 1/Phase 2
Study of ADI-PEG20 with chemo for aggressive prostate cancer
This study tests a combination of three drugs—ADI-PEG20, carboplatin, and cabazitaxel—in men with aggressive variant prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink or slow the cancer.
Houston, TexasAges 18 years+ - NCT06037954Recruiting
Mental health support for older adults with cancer
This study offers mental health care for older adults (65+) with breast, colorectal, lung, or prostate cancer who are getting treatment or recently finished. It aims to help people who are also feeling depressed.
New York, New YorkAges 65 years+ - NCT03408964Recruiting
Blood tests to predict treatment response in prostate cancer
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
BellinzonaAges 18 years+
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer?
- Yes. Clin2 currently lists 1,212 recruiting prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.